If you have been reading about Stenabolic and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
==== Rhizome lotus ==== Rhizome lotus cultivars produce a higher yield and higher quality rhizomes than seed or flower lotus cultivars. Furthermore, this group grows tall and produces few to no flowers. Cultivars can be classified by harvest time or by the depth of rhizomes into these types:
Samba(in German) - Gambian Physician, former president Of Gambia Football Federation, former World Health Organization WHO Regional Director For Africa. Bai Lamin Jobe(in German - Former Minister Of Works, Transportation And infrastructure. Samba D. Bah (in German) - Former DG State intelligence Service. Ousman A. Bah(in German) - Former Minister Of Communication and Technology. Mary Sey - Jurist, former justice of The Supreme court Of Gambia. Fatou Mass Jobe-Njie - former Minister of Tourism and Culture. Pa Jallow (Diplomat)(in German) - Former DG State intelligence service. Cherno Jallow – Lawyer and Judge. Justice of the Supreme Court of the Gambia, former attorney general of the British Virgin Islands, Gambia Hamat Bah – Politician. Current Minister of Tourism and Culture; leader of the National Reconciliation Party (NRP), Gambia Omar A. Jallow – Politician. former Minister of Agriculture, leader of the People's Progressive Party, Gambia Halifa Sallah – former Special Advisor to the president on Governance and the spokesperson for President Adama Barrow's administration, former National Assembly Minority Leader, Secretary-general of the People's Democratic Organisation for Independence and Socialism, Gambia Momodou Lamin Sedat Jobe - Diplomat, former Gambian foreign minister Mama Kandeh- leader opposition Gambia Democratic Congress, and former parliamentarian Bubacarr Bah - Professor of Mathematics, German Research Chair of Mathematics with specialization in Data Science at AIMS South Africa. Haddy Jallow- actress, Gambia.
=== Oncology === Signatera is the first circulating tumor DNA (ctDNA) assay built for molecular residual disease (MRD) detection and cancer recurrence monitoring. In 2020, Signatera received the CE Mark, as well as final Medicare coverage in stage II-III colorectal cancer and draft coverage in immunotherapy response monitoring. Signatera has been clinically validated to detect colorectal cancer recurrence up to 16.5 months in advance of radiologic imaging and early-stage breast cancer up to two years earlier than imaging.
== Research history == GLP-1 was first described 1979 by a research group of Werner Creutzfeldt in Göttingen. Also Jens Juul Holst worked in this area. In the early 1980s, Richard Goodman and P. Kay Lund were postdoctoral researchers working in Joel Habener's laboratory at Massachusetts General Hospital. Starting in 1979, Goodman harvested DNA from American anglerfish islet cells and spliced the DNA into bacteria to find the gene for somatostatin; Lund then joined the Habener laboratory and used Goodman's bacteria to identify the gene for glucagon. In 1982, they published their discovery that the gene for proglucagon actually codes for three peptides, namely glucagon and two novel peptides. Those two novel peptides were later isolated, identified, and investigated by other researchers, and are now known as glucagon-like peptide-1 and glucagon-like peptide-2. In the 1980s, Svetlana Mojsov worked on the identification of GLP-1 at Massachusetts General Hospital, where she was head of a peptide synthesis facility. To try to identify whether a specific fragment of GLP-q was an incretin, Mojsov created an incretin-antibody and developed ways to track its presence. She identified that a stretch of 31 amino acids in the GLP-1 was an incretin. Mojsov and her collaborators Daniel J. Drucker and Habener showed that small quantities of laboratory-synthesized GLP-1 could trigger insulin. Mojsov fought to have her name included in patents, with Mass General eventually agreeing to amend four patents to include her name. She received her one-third of drug royalties for one year.
Sources: en.wikipedia.org
BCG has been one of the most successful immunotherapies. BCG vaccine has been the "standard of care for patients with bladder cancer (NMIBC)" since 1977. By 2014, more than eight different considered biosimilar agents or strains were used to treat nonmuscle-invasive bladder cancer.
With the announcement of GPT-2 in 2019, OpenAI originally planned to keep the source code of their models private citing concerns about malicious applications. After OpenAI faced public backlash, however, it released the source code for GPT-2 to GitHub three months after its release. OpenAI did not publicly release the source code or pretrained weights for the GPT-3 model. At the time of GPT-3's release, GPT-2 was still the most powerful open source language model in the world. 2022 also saw the rise of larger and more powerful models under licenses of varying openness including Meta's OPT. The Open Source Initiative consulted experts over two years to create a definition of "open-source" that would fit the needs of AI software and models. The most controversial aspect relates to data access, since some models are trained on sensitive data which can't be released. In 2024, they published the Open Source AI Definition 1.0 (OSAID 1.0). It requires full release of the software for processing the data, training the model and making inferences from the model. For the data, it only requires access to details about the data used to train the AI so others can understand and re-create it. On August 22, 2022, open-source text-to-image model Stable Diffusion was first released. In 2023, Meta's weights-available Llama 1 and 2, and Mistral AI's open-weight Mistral and Mixtral models were first released, along with MosaicML's smaller open-source models. The release of the Llama models was a milestone in generating interest in open-weight and open-source models.
== A == Acinetobacter Acinetobacter baumannii Actinomyces Actinomyces israelii Actinomyces gerencseriae Agrobacterium radiobacter Agrobacterium tumefaciens Anaplasma Anaplasma phagocytophilum Anaplasma sparouinense Arcanobacterium haemolyticum Azorhizobium caulinodans Azotobacter vinelandii
== Prognosis == Prognosis varies with the type of amyloidosis and the affected organ system. Prognosis for untreated AL cardiac amyloidosis is poor, with a median survival of six months. More specifically, AL amyloidosis can be classified as stage I, II or III based on cardiac biomarkers like Nt-proBNP and cardiac troponin. Survival diminishes with increasing stage, but recent advancements in treatments have improved median survival rates for stages I, II, and III, to 91.2, 60, and 7 months respectively. Outcomes in a person with AA amyloidosis depend on the underlying disease, organ(s) affected, and correlate with the concentration of serum amyloid A protein. People with ATTR, mutant ATTR and wild-type ATTR have a better prognosis when compared to people with AL and may survive for over a decade. Survival time is not associated with gender or age, however, some measures of reduced heart function are associated with a shorter survival time. Senile systemic amyloidosis was determined to be the primary cause of death for 70% of people over 110 who have been autopsied.
== Clinical significance == Poly- or oligotuftsin derivatives can be used as delivery systems. For example, a 35-40 unit repeat was used as a carrier for the preparation of synthetic immunogens in malaria vaccines against Plasmodium falciparum. Tuftsin enhances the action of rifampicin-bearing liposomes in the treatment of tuberculosis, and that amphotericin B-bearing liposomes in the treatment of human aspergillosis in mice. Conjugates with polytuftsin retain tuftsin-like effects and increase the epitope specific antibody production.
Sources: en.wikipedia.org
The MMRV vaccine is a combination vaccine against measles, mumps, rubella (German measles), and varicella (chickenpox). It contains the combined measles vaccine, mumps vaccine, rubella vaccine, and varicella vaccine into a single injection. The MMRV vaccine has similar immunogenicity and overall safety profiles to the MMR vaccine administered with or without the varicella vaccine. The MMRV vaccine is typically given to children between one and two years of age. Several companies supply MMRV vaccines. Proquad is marketed by Merck and was approved in 2005, for use in the United States for children aged twelve months of age through twelve years of age. Stand-alone virus measles, mumps, rubella, and varicella vaccines had been previously licensed in 1963, 1967, 1969, and 1995, respectively. An MMRV vaccine called Priorix Tetra by GlaxoSmithKline is available in some of the member states of the European Union.
The antimicrobial resistance crisis also extends to the food industry, specifically with food producing animals. With an ever-increasing human population, there is constant pressure to intensify productivity in many agricultural sectors, including the production of meat as a source of protein. Antibiotics are fed to livestock to act as growth supplements, and a preventive measure to decrease the likelihood of infections. Farmers typically use antibiotics in animal feed to improve growth rates and prevent infections. However, this is illogical as antibiotics are used to treat infections and not prevent infections. 80% of antibiotic use in the U.S. is for agricultural purposes and about 70% of these are medically important. Overusing antibiotics gives the bacteria time to adapt leaving higher doses or even stronger antibiotics needed to combat the infection. Though antibiotics for growth promotion were banned throughout the EU in 2006, 40 countries still use antibiotics to promote growth. This can result in the transfer of resistant bacterial strains into the food that humans eat, causing potentially fatal transfer of disease. While the practice of using antibiotics as growth promoters does result in better yields and meat products, it is a major issue and needs to be decreased to prevent antimicrobial resistance.
Santa Fe College is a public college in Gainesville, Florida, United States. It is part of the Florida College System and offers both associate and baccalaureate degree programs. Established in 1965 by the Florida Legislature as Santa Fe Junior College, the institution began classes in September 1966. It was renamed Santa Fe Community College in 1972 and became "Santa Fe College" in 2008 to highlight its baccalaureate programs.
However, if the analyte being tested has a low mass value then it can produce a similar looking spectra to that of a MALDI spectra. ME-SIMS has been so effective that it has been able to detect low mass chemicals at sub cellular levels that was not possible prior to the development of the ME-SIMS technique. The second technique being used is called sample metallization (Meta-SIMS) - This is the process of gold or silver addition to the sample. This forms a layer of gold or silver around the sample and it is normally no more than 1-3 nm thick. Using this technique has resulted in an increase of sensitivity for larger mass samples. The addition of the metallic layer also allows for the conversion of insulating samples to conducting samples, thus charge compensation within SIMS experiments is no longer required. Subcellular (50 nm) resolution is enabled by NanoSIMS allowing for absolute quantitative analysis at the organelle level.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.